Breaking News Instant updates and real-time market news.

ALKS

Alkermes

$18.42

0.01 (0.05%)

07:07
10/23/19
10/23
07:07
10/23/19
07:07

Alkermes raises FY19 non-GAAP EPS view to 44c-57c from 36c-45c, consensus 34c

Backs FY19 revenue view of $1.14B-$1.19B, consensus $1.18B. Alkermes lowers CapEx view to $80M-$90m from $90M-$100M. Expects a restructuring charge of approximately $15M.

  • 23

    Oct

  • 06

    Nov

ALKS Alkermes
$18.42

0.01 (0.05%)

07/30/19
HCWC
07/30/19
NO CHANGE
Target $28
HCWC
Neutral
Alkermes settlement close to best-case scenario, says H.C. Wainwright
H.C. Wainwright analyst Douglas Tsao says Alkermes' (ALKS) settlement and license agreement with Amneal Pharmaceuticals (AMRX) provides a "measure of needed visibility." There was some investor nervousness coming into the hearing and this settlement "represents close to a best-case scenario for Alkermes," Tsao tells investors in a research note. Vivitrol's growth has slowed but 12% volume growth in Q2 indicates the franchise can continue to be a contributor for the foreseeable future, adds the analyst. Tsao thinks the bull thesis for Alkermes hinges largely on the prospects for ALKS-4230. The update that patients on ALKS-4230 appear to avoid capillary leak syndrome, which has limited the utility of IL-2 therapies in the past, is important, according to Tsao. He keeps a Neutral rating on Alkermes with a $28 price target.
07/30/19
JPMS
07/30/19
NO CHANGE
JPMS
Overweight
Alkermes, Biogen data a positive, but questions remain, says JPMorgan
JPMorgan analyst Cory Kasimov views the data this morning from Alkermes (ALKS) and Biogen (BIIB) as an incremental positive but he believes commercial questions remain for Vumerity. The analyst has an Overweight rating on Alkermes and Neutral rating on Biogen. How doctors will view this dataset and how aggressive Biogen will be in launching Vumerity in the face of questions regarding Tecfidera's ultimate runway are the next key questions, Kasimov tells investors in a research note. However, he calls this morning's news a "good-to-see outcome."
07/30/19
PIPR
07/30/19
NO CHANGE
PIPR
Neutral
Piper says Alkermes scores 'back-to-back wins' with settlement, Biogen data
Piper Jaffray analyst Danielle Brill said Alkermes (ALKS) has scored "back-to-back wins" with its announcement yesterday that it settled the ongoing Vivitrol patent dispute with Amneal (AMRX) and the news this morning that BIIB098 showed a statistically significant improvement on GI tolerability versus Tecfidera in a head-to-head Phase 3 trial. She still questions how meaningful the improvement in GI tolerability actually is, but thinks the drug may become a priority for partner Biogen (BIIB), Brill tells investors. The analyst, who views the news of the last two days as net positive for Alkermes, maintains her concerns about long-term value creation and the company's "dry pipeline," she said. Brill keeps a Neutral rating on Alkermes shares.
09/05/19
MSCO
09/05/19
UPGRADE
Target $20
MSCO
Equal Weight
Alkermes upgraded to Equal Weight from Underweight at Morgan Stanley
Morgan Stanley analyst David Risinger upgraded Alkermes to Equal Weight from Underweight while lowering his price target for the shares to $20 from $30. The stock has underperformed, and recent developments eliminated the worst-case scenarios for Vumerity trial results and Vivitrol's patent, Risinger tells investors in a research note. Although cancer pipeline candidate ALKS 4230 could still disappoint, consensus expectations are low due to a questionable profile, adds the analyst. He believes Alkermes' long-term risk to royalty streams is balanced by its pipeline or cost savings optionality at current share levels.

TODAY'S FREE FLY STORIES

WORK

Slack Technologies

$21.18

-0.12 (-0.56%)

11:35
11/14/19
11/14
11:35
11/14/19
11:35
Options
Slack put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

11:35
11/14/19
11/14
11:35
11/14/19
11:35
General news
Chair Powell said modern monetary theory (MMT) "is just wrong," »

Chair Powell said modern…

QGEN

Qiagen

$36.81

1.29 (3.63%)

11:32
11/14/19
11/14
11:32
11/14/19
11:32
Upgrade
Qiagen rating change  »

Qiagen upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

11:30
11/14/19
11/14
11:30
11/14/19
11:30
General news
Breaking General news story  »

San Francisco Federal…

11:30
11/14/19
11/14
11:30
11/14/19
11:30
General news
Breaking General news story  »

San Francisco Federal…

VREOF

Vireo Health

$0.00

(0.00%)

, CGC

Canopy Growth

$15.28

-3.24 (-17.49%)

11:28
11/14/19
11/14
11:28
11/14/19
11:28
On The Fly
Rising High: An exclusive talk with multi-state cannabis company Vireo Health »

In this edition of…

VREOF

Vireo Health

$0.00

(0.00%)

CGC

Canopy Growth

$15.28

-3.24 (-17.49%)

APHA

Aphria

$4.14

-0.32 (-7.17%)

ACB

Aurora Cannabis

$3.17

-0.37 (-10.45%)

CVSI

CV Sciences

$0.00

(0.00%)

CTST

CannTrust

$0.92

-0.0569 (-5.85%)

CRON

Cronos Group

$6.78

-0.49 (-6.74%)

CANN

General Cannabis

$0.00

(0.00%)

IGC

India Globalization Capital

$0.81

-0.0228 (-2.74%)

TLRY

Tilray

$19.55

-1.41 (-6.73%)

TCNNF

Trulieve Cannabis

$0.00

(0.00%)

ZYNE

Zynerba

$6.06

-0.35 (-5.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 14

    Nov

  • 19

    Nov

X

U.S. Steel

$12.80

-0.62 (-4.62%)

11:25
11/14/19
11/14
11:25
11/14/19
11:25
Options
US Steel call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:25
11/14/19
11/14
11:25
11/14/19
11:25
General news
Powell: passing USMCA would benefit the economy »

Powell: passing USMCA…

11:25
11/14/19
11/14
11:25
11/14/19
11:25
General news
Today's U.S. reports »

Today's U.S. reports…

DLTR

Dollar Tree

$108.85

0.445 (0.41%)

11:21
11/14/19
11/14
11:21
11/14/19
11:21
Hot Stocks
FDA sends warning letter to Dollar Tree regarding violations at drug suppliers »

In an FDA warning letter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
11/14/19
11/14
11:17
11/14/19
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
11/14/19
11/14
11:16
11/14/19
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:15
11/14/19
11/14
11:15
11/14/19
11:15
General news
Powell on changing policy: »

Powell on changing…

11:15
11/14/19
11/14
11:15
11/14/19
11:15
General news
Breaking General news story  »

4-Week Bill Auction to be…

11:15
11/14/19
11/14
11:15
11/14/19
11:15
General news
Breaking General news story  »

8-Week Bill Auction to be…

BA

Boeing

$362.00

-0.42 (-0.12%)

11:14
11/14/19
11/14
11:14
11/14/19
11:14
Hot Stocks
Breaking Hot Stocks news story on Boeing »

Boeing moves to session…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

11:11
11/14/19
11/14
11:11
11/14/19
11:11
General news
3-Month Bill Announcement Offering Amount data reported »

3-Month Bill Announcement…

11:11
11/14/19
11/14
11:11
11/14/19
11:11
General news
10-Yr TIPS Announcement CUSIP Number data reported »

10-Yr TIPS Announcement…

11:11
11/14/19
11/14
11:11
11/14/19
11:11
General news
10-Yr TIPS Announcement Offering Amount data reported »

10-Yr TIPS Announcement…

11:10
11/14/19
11/14
11:10
11/14/19
11:10
General news
6-Month Bill Announcement Offering Amount data reported »

6-Month Bill Announcement…

BMRN

BioMarin

$75.55

-0.54 (-0.71%)

11:07
11/14/19
11/14
11:07
11/14/19
11:07
Hot Stocks
BioMarin sees GAAP break-even or better in 2020 assuming Valoctocogene launch »

BioMarin Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

GILD

Gilead

$62.48

-0.85 (-1.34%)

11:05
11/14/19
11/14
11:05
11/14/19
11:05
Options
Gilead call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

11:05
11/14/19
11/14
11:05
11/14/19
11:05
General news
Powell:the day of reckoning could be "quite far off," »

Powell:the day of…

USO

United States Oil Fund

$12.05

0.09 (0.75%)

11:00
11/14/19
11/14
11:00
11/14/19
11:00
General news
Crude inventories for week of November 8 »

Crude oil inventories…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$263.91

-0.61 (-0.23%)

10:58
11/14/19
11/14
10:58
11/14/19
10:58
On The Fly
Maxim says sell Apple on concern about 2020 iPhone sales »

Maxim analyst Nehal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.